Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (1505)	2/11/1999 8:19:00 PM
From: Dave Gore	Read Replies (2) \| Respond to of 2135

I am told Dan Rather/CBS News doing a full minute piece tonight. Is that right? Well, I'll be watching just in case!

To: Andrew H who wrote (1505)	2/11/1999 8:24:00 PM
From: Anthony@Pacific	Read Replies (3) \| Respond to of 2135

ENMD<--------SELL/SHORT @ 26 1/2 ( stock should trade around 7 to 8 based on 4 times cash ) Lets be realistic ..they are years away from any thing that could possibly even come close to helping humansand are a decade away from any commercial use...We saw this before and we know what happened last time...The Bristol Myers news killed it and should not be discounted ..There are those on this thread who claim to know more than the powers that be at Bristol Myers....Now In all honesty I was more impressed with GERN's stem cell studies about being able to regenerate tissue and the prospect of immortal cells..ENMD is nothing but a pipe dream at this point in time and I have initiated coverage of this stock at current levels with an immediate Sell/SHORT

To: Andrew H who wrote (1505)	2/11/1999 8:48:00 PM
From: Pluvia	Read Replies (1) \| Respond to of 2135

<<The fact that the NCI managed to replicate shows that these compounds are indeed volatile and difficult to handle but with the proper care, it can be done.>> A volatile compound is a worthless compound IMO, if it is ever to be mass marketed - should it even show enough promise to be studied in humans. Even with human trial, you are looking at years during which time this stock will crater. Heck these guys don't even have a handle on how to produce the drug - and you're giddy about it? GMAFB Longs typically overlook the problems only focusing on the potential. Reality sets in when the stock goes down and the company goes broke. Longs should thank their luck stars they have the opportunity to exit again with their ass in hand. Cheers Steve